Superior Colliculus Activity in Parkinson Disease: a Potential Marker?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

23 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-10-07

Study Completion Date

2018-01-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ultimate goal of this project is to evaluate a possible new strategy to diagnose earlier Parkinson's disease, using the superior colliculus as a biomarker.

Preliminary data from the investigator's group in a rat model of Parkinson's disease suggest that the superior colliculus, a sensory structure, show an early deficit in visual processing. The investigator's data also suggests that with the evolution of the disease, this structure presents a neuronal re-organisation leading which causes a sensory rebound after the introduction of the treatment. The light responses in the superior colliculus were faster, bigger in amplitude and lasted longer (Rolland et al., 2012). Those results raise an important question about the superior colliculus functional state in Parkinson's patients. If this structure have a similar neuroplasticity, the investigators could hypothesize that the superior colliculus may also present a sensory rebound when introducing the treatment. If this hypothesis is true, the accelerated and amplified light responses of this structure may explain the difficulties felt by the patients to inhibit reflexive saccades induced by the appearance of unexpected visual stimuli. Indeed, the superior colliculus is involved in the orientation of the head and eye toward any sudden changes in our environment (Wurtz and Albano, 1980) and the light responses of this structure are strongly correlated with the speed of the saccade (Marino et al., 2012).

Therefore, the investigators want to test if a similar deficit could be observed in the superior colliculus of newly diagnosed PD patients. Data will be compared to matching controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Eye Movements (EYE) as Early Markers of Brain Dysfunction (BRAIN) in Parkinson's Disease (PARK)

NCT04212637

Parkinson Disease

UNKNOWN NA

Visual Selective Attention in Parkinson's Disease

NCT01135407

Visual Attention in Parkinson's Disease

COMPLETED

Video-oculography and Parkinson's Disease

NCT04731246

Parkinson Disease, Idiopathic

RECRUITING NA

Assessment of Pupil Light Responses in Patients With Parkinson Disease

NCT04117555

Parkinson Disease

RECRUITING

White Matter Pathology in Parkinson's Disease (PD)

NCT01039831

White Matter Lesions Postural Instability Gait Disorders

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This project aims at better understanding the physiopathology of Parkinson's disease and the effect of the administration of the classical medical treatment. The main aim of this project is to evaluate the possibility of an early detection using a new original strategy. The investigators want to demonstrate the predictive value of the superior colliculus light responses as an early biomarker.

The investigators will perform functional magnetic resonance imagery (fMRI) to measure the BOLD light responses of the superior colliculus at different key stages of the normal medical follow up of Parkinson's patients by the neurologist (when diagnosed, when introducing the first treatment and when the treatment is stabilised).

Two groups of participants will be tested: a) a group of de novo patients, which have just been diagnosed and haven't started their treatment; b) a group of matching controls.

A first fMRI session (S1) will be performed to compare the light induced BOLD response of the superior colliculus between de novo patients and their matching controls. This session will evaluate a possible visual processing dysfunction in the superior colliculus of newly diagnosed patients.

Parkinson's patients will then start their treatment and a second session (S2) will be done on this group shortly after the introduction of the treatment to measure its acute effect. If the superior colliculus of those patients presents a sensory rebound, the investigators should observe a bigger light-induced BOLD response after the treatment compared to before the treatment.

A third session (S3) will be performed after the optimal adjustment of the treatment on motor symptoms which would be around six month after the start of the treatment. This adjustment is long and difficult, realized by the neurologist according to its effect on the motor symptoms. Those two last fMRI will allow the investigators to compare the effect of the introduction of the treatment on the motor symptoms, known to not improve correctly at this stage, and on non-motor symptoms (visual processing deficits in this project) from which no information are available to the investigators knowledge.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

de novo Parkinson's patients

This group includes de novo Parkinson's patients who have just been diagnosed and not started their treatment at the inclusion.

This group will perform three fMRI sessions at different crucial steps of their normal follow up with a neurologist. Their visual abilities will be tested with an ophthalmologic evaluation and their sensitivity to contrast with a visual psycho-physics test.

fMRI

Intervention Type OTHER

The investigators will use a non invasive fMRI technique centred on the superior colliculus during the presentation of flickered check-boards with varying contrast (1, 3, 5 and 9 %).

Ophthalmologic evaluation

Intervention Type OTHER

The aim of this experiment is the evaluate the functional state of a visual structure. Therefore, with this ophthalmologic test, the investigators will control if the participant does not present major visual deficits. This examination will evaluate the visual acuity and the visual field. A funduscopic examination will also be performed to check the retina.

visual psychophysics test

Intervention Type OTHER

This test will allow to control the sensitivity of the participant to our contrast. The participant will be asked to look at screen on which three static check-boards will be presented. The participant will have to choose the two check-boards with the closest contrast.

matching controls

This group includes age-matching control participants to the first Parkinson group.

This group will perform one fMRI session. Their visual abilities will be tested with an ophthalmologic evaluation and their sensitivity to contrast with a visual psycho-physics test.

fMRI

Intervention Type OTHER

The investigators will use a non invasive fMRI technique centred on the superior colliculus during the presentation of flickered check-boards with varying contrast (1, 3, 5 and 9 %).

Ophthalmologic evaluation

Intervention Type OTHER

The aim of this experiment is the evaluate the functional state of a visual structure. Therefore, with this ophthalmologic test, the investigators will control if the participant does not present major visual deficits. This examination will evaluate the visual acuity and the visual field. A funduscopic examination will also be performed to check the retina.

visual psychophysics test

Intervention Type OTHER

This test will allow to control the sensitivity of the participant to our contrast. The participant will be asked to look at screen on which three static check-boards will be presented. The participant will have to choose the two check-boards with the closest contrast.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fMRI

The investigators will use a non invasive fMRI technique centred on the superior colliculus during the presentation of flickered check-boards with varying contrast (1, 3, 5 and 9 %).

Intervention Type OTHER

Ophthalmologic evaluation

The aim of this experiment is the evaluate the functional state of a visual structure. Therefore, with this ophthalmologic test, the investigators will control if the participant does not present major visual deficits. This examination will evaluate the visual acuity and the visual field. A funduscopic examination will also be performed to check the retina.

Intervention Type OTHER

visual psychophysics test

This test will allow to control the sensitivity of the participant to our contrast. The participant will be asked to look at screen on which three static check-boards will be presented. The participant will have to choose the two check-boards with the closest contrast.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* De novo parkinson's patients being just diagnosed (stage 1 according to the Hoehn and Yahr scale: first unilateral signs with no discomfort in everyday life) without a current dopaminergic treatment and who have not started their anti-parkinsonian treatment.
* Both Parkinson's patients and their age matching control must not present a major visual pathology (mainly in the retina) which may interfere with the visual task.
* Signed informed and free consent.
* Matching controls must not present a neurological or psychiatric troubles.
* For the matching controls: There are no contraindication on current treatments apart from those to treat other neurological disease than Parkinson's disease or psychiatric troubles.
* For Parkinson's patients: There are no contraindication on current treatments apart from those to treat neurological troubles including anti-parkinsonian treatment, or psychiatric troubles.
* As a precaution, the investigators will check that no MRI exam has been performed during the week preceding our fMRI.

Exclusion Criteria

* Parkinson's patients with important tremor limiting the validity of the fMRI acquisition.
* Adult under supervision
* Incapacity to understand the consent explanations.
* Impossibility to participate to the whole experimental protocol.
* No affiliation to a health insurance.
* Consent not signed by a participant or refusal by the participant to participate to the experiment.
* Pregnancy or breast feeding woman.
* Administrative or justice freedom restricted participant.

* Pacemaker, neurosensorial stimulator or implanted defibrillator.
* Presence of ocular or cerebral ferromagnetic material.
* Respiratory disease (i.e. asthma), cardio-vascular deficits, claustrophobia

Minimum Eligible Age

35 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes